Biological variation of galectin-3 and soluble ST2 for chronic heart failure: Implication on interpretation of test results

American Heart Journal

Volumn 165, Issue 6, 2013, Pages 995-999

  Wu, Alan H B ^a   Wians, Frank ^b   Jaffe, Allan ^c  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

^b Clinical Pathology Laboratory Inc   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; GALECTIN 3; PROTEIN; SST2 PROTEIN; TROPONIN I; TROPONIN T; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL CHEMISTRY; DIAGNOSTIC ACCURACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART FAILURE; HUMAN; INDIVIDUALITY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

EID: 84880072700     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2013.02.029     Document Type: Article

References (35)

1. McMurray JJV, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J 2012;33:1787-847.
2. Fraser CG, Harris EK. Generation and application of data on biological variation in clinical chemistry. Crit Rev Clin Lab Sci 1989; 27:409-37.
3. Lu J, Snider JV, Grenache DG. Establishment of reference intervals for soluble sST2 from a United States population. Clin Chim Acta 2010; 411:1925-6.
4. Christenson RH, Duh SH, Wu AHB, et al. Multi-center determination of galectin-3 assay performance characteristics: Anatomy of a novel assay for use in heart failure. Clin Biochem 2010;43:683-90.
5. Wu AHB, Lu A, Todd J, et al. Short-and long-term biological variation in cardiac troponin I with a high-sensitivity assay: Implications for clinical practice. Clin Chem 2009;55:52-8.
6. Brooks ZC. Performance driven quality control. Washington, DC: AACC Press; 2001. p. 46.
7. Wu AHB, Smith A, Wians FH. Interpretation of creatine kinase and aldolase for statin-induced myopathy: Reliance on serial testing based on biological variation. Clin Chim Acta 2009;399:109-11.
8. Wu AHB, Smith AC, Mather JF, et al. Biological variation for NT-proand B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. Am J Cardiol 2003;92:628-31.
9. Wu AHB, Akhigbe P, Wians F. Long-term biological variation in cardiac troponin I. Clin Biochem 2012;45:714-6.
10. Frankenstein L, Wians F, Wu AHB, et al. Biological variation and reference change value of high sensitivity troponin T in healthy individuals during short and intermediate follow-up periods. Clin Chem 2011;57:1068-71.
11. Dieplinger B, Januzzi JL, Steinmair M, et al. Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble sST2 in human plasma. The Presage ST assay. Clin Chim Acta 2009;409:33-40.
12. Maisel AS. Use of BNP levels in monitoring hospitalized heart failure patients with heart failure. Heart Failure Rev 2003;8:339-44.
13. Logeart D, Thabut G, Jourdain P, et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk for re-admission after decompensated heart failure. J Am Coll Cardiol 2004;43: 635-41.
14. Takeda Y, Fukutomi T, Suzuki S, et al. Effect of carvelidol on plasma Btype natriuretic peptide concentrations and symptoms in patients with heart failure and preserved ejection fraction. Am J Cardiol 2004;94: 448-53.
15. Hara Y, Hamada M, Shigematsu Y, et al. Effect of beta-blocker on left ventricular function and natriuretic peptides in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitor. Jap Circ J 2000;64:365-9.
16. Latini R, Masson S, Anand I, et al. Effects of valsartan on circulation brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure. The Valsartan Heart Failure Trial (Val-HeFT). Circulation 2002;106:2454-8.
17. Sheth T, Parker T, Block A, et al. Comparison of the effects of omapatrilat and lisinopril on circulating neurohormones and cytokines in patients with chronic heart failure. Am J Cardiol 2002; 90:496-500.
18. Wu AHB. Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: The role of biological variation in interpretation of results. Am Heart J 2006;152:828-34.
19. Porapakkham P, Porapakkham P, Zimmett H, et al. B-type natriuretic peptide-guided heart failure therapy. A meta-analysis. Arch Intern Med 2010;170:507-14.
20. Januzzi Jr JL, Rehman SU, Mohammed AA, et al. Use of aminoterminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol 2011;58:1881-9.
21. Briedthardt T, Socrates T, Drexler B, et al. Interleukin family member sST2 rapidly responds to heart failure treatment and its changes predict one-year mortality. Eur Heart J 2011;32:125 Abstract #P805.
22. de Boer RA, Lok AJA, Jaarsma T, et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 2011;43:60-8.
23. Keevil BG, Kilpatrick ES, Nichols SP, et al. Biological variation of cystatin C: Implications for the assessment of glomerular filtration rate. Clin Chem 1998;44:1535-9.
24. Babuin L, Jaffe AS. Troponin: The biomarker of choice for the detection of cardiac injury. CMAJ 2005;173:1191-202.
25. Keller T, Zeller T, Ojeda F, et al. Serial changes in highly sensitive troponin I assay and early diagnosis of myocardial infarction. JAMA 2011;306:2684-93.
26. Lok DJA, Van Der Meer P, Bruggink PW, et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: Data from the DEAL-HF study. Clin Res Cardiol 2010;99: 323-8.
27. Gullestad L, Ueland T, Kjekshus J, et al. Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure. (CORONA). Eur Heart J 2012, http: //dx.doi.org/10.1093/eurheartj/ ehs077.
28. Ky B, French B, McCloskey K, et al. High-sensitivity sST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail 2011;4: 180-7.
29. Boisot S, Beede J, Isakson S, et al. Serial sampling of sST2 predicts 90-day mortality following destabilized heart failure. J Cardiac Fail 2008;14:732-8.
30. Chen HH, Burnett JC. Natriuretic peptides in the pathophysiology of congestive heart failure. Curr Cardiol Rep 2000;2:198-205.
31. Clerico A, Zucchelli GC, Pilo A, et al. Clinical relevance of biological variation of B-type natriuretic peptide. Clin Chem 2005; 51:925-6.
32. Bruins S, Fokkema R, Pomer JWP, et al. High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure. Clin Chem 2004;50: 2052-8.
33. Nordenskjold AM, Ahlstrom H, Eggers KM, et al. Short-and longterm individual variation in cardiac troponin in patients with stable coronary artery disease. Clin Chem 2013;59 [epub ahead of print].
34. Lok DJA, Van Der Meer P, Bruggink-Andre de la Porte PW, et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: Data from the DEAL-HF study. Clin Res Cardiol 2010;99:323-8.
35. Coglianese EE, Larson MG, Vasan RS, et al. Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study. Clin Chem 2012;58:1673-81.